Our Board of Directors has been selected on their individual skills and contribution to Pacific Edge
Members of the Board of Directors represent a wide range of business skills, a deep rooted understanding of the global financial environment and broad experience in biomedical start-ups and the global biomedical marketplace.
|David Darling||Executive Director||2014|
Chris joined the Board in 2016 and was appointed as Chairman in August 2016. A New Zealand citizen resident in Melbourne, Chris has held senior positions in both CEO and CFO roles with a number of large international companies and was a partner in Arthur Young, Chartered Accountants. Prior to retiring from full time corporate life, he was CFO of Fulton Hogan, a large NZ resources based civil contractor. Chris holds a BCom from Otago University and is a Chartered Accountant and a member of the Australian Institute of Company Directors.
Dave has over 30 years’ business experience in life sciences and biotechnology and was appointed to the Board as Executive Director in 2014. In his capacity as Chief Executive Officer he has led Pacific Edge from its early inception, and has significant executive and leadership experience in the development and international commercialisation of biomedical and biotechnology businesses and products. During his career, Dave has held a number of positions in governance, executive and senior management, joining Pacific Edge from Fletcher Challenge.
Anatole is the co-founder of Artemis Capital, a private equity investment firm based in Auckland. He graduated from the University of Auckland with an MCom (Hons) in Finance and Economics. Following that he spent eight years with Air New Zealand / Ansett, holding senior positions in Pricing, Revenue Management and Systems implementation. He holds directorships in numerous private companies and and has significant knowledge of financial capital markets.
Sarah brings international corporate finance experience to Pacific Edge after a professional career with PricewaterhouseCoopers in New Zealand and HSBC Investment Bank in London. During her executive career, Sarah has worked in mergers and acquisitions, equity capital markets and equity research. She also had a lead role in investor relations and venture capital raisings in Asia, the Middle East and Europe for US based biopharmaceutical companies. Sarah has a degree in Economics from the University of Edinburgh.
Bryan is an internationally recognised cancer researcher and research administrator, with significant business experience. He has held a number of governance roles, including with a NASDAQ listed biotech company. Bryan was a Director of Cancer Trials Australia, Director of the Monash Institute of Medical Research, and Director and CEO of the Hudson Institute of Medical Research. He is currently Emeritus Director and Distinguished Scientist at the Hudson Institute in Melbourne. He has a BSc (Hons) and PhD in Microbiology from the University of Otago.
Anna has a successful 25+ year track record in leading and driving transformational change within the pharmaceutical sector. She has significant global business experience having held a variety of senior executive roles within NZ, Asia Pacific and Europe, most recently as NZ General Manager for GlaxoSmthKline. She has a strong passion to improve the quality of lives for all & thrives on new challenges. Anna’s drive is to support businesses with strategic growth, best practice governance & improving outcomes.
Anna is also a Director of Rua Bioscience and Deputy Chair of TAB New Zealand.
Previous governance roles include Chair of Global Women, Director of Medicines New Zealand, Vice Chair of Pukekohe Park and Vice Chair of Shooting Star Hospice, the first Children’s Hospice in London, UK.
Mark is an experienced corporate finance professional, with approximately 25 years of experience in the Australasian capital, corporate and financial markets. He was an Executive Director for Investment Banking at Goldman Sachs where he worked for nearly 20 years and has been involved in many large prominent New Zealand transactions including the IPOs of Meridian, Mighty River Power and Vector. Mark is a Director of a number of entities including being Chair of Astrolab VC Investment Committee and a Director of Mariposa Holdings (a large charitable organisation).
Pacific Edge utilises experienced patent attorneys in both NZ and the US to support our intellectual property strategies
Our products support the early diagnosis and better management of cancer